This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Sionna Therapeutics, Inc. (SION), Celldex (CLDX) and Jazz Pharmaceuticals (JAZZ)

Tipranks - Tipranks - Fri Jun 19, 6:54AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Sionna Therapeutics, Inc. (SION), Celldex (CLDX) and Jazz Pharmaceuticals (JAZZ) with bullish sentiments.

Claim 55% Off TipRanks

Sionna Therapeutics, Inc. (SION)

LifeSci Capital analyst Gaurav Maini maintained a Buy rating on Sionna Therapeutics, Inc. today and set a price target of $60.00. The company’s shares closed last Wednesday at $36.73.

According to TipRanks.com, Maini is a 3-star analyst with an average return of 8.7% and a 50.0% success rate. Maini covers the Healthcare sector, focusing on stocks such as Inhibikase Therapeutics, Liquidia Technologies, and Tectonic Therapeutic. ;'>

Currently, the analyst consensus on Sionna Therapeutics, Inc. is a Moderate Buy with an average price target of $51.71.

See today’s best-performing stocks on TipRanks >>

Celldex (CLDX)

UBS analyst David Dai maintained a Buy rating on Celldex on June 16 and set a price target of $45.00. The company’s shares closed last Wednesday at $32.93.

According to TipRanks.com, Dai is a 3-star analyst with an average return of 5.5% and a 54.9% success rate. Dai covers the Healthcare sector, focusing on stocks such as Janux Therapeutics Inc, Syndax Pharmaceuticals, and Telix Pharmaceuticals. ;'>

Currently, the analyst consensus on Celldex is a Strong Buy with an average price target of $51.10, a 56.8% upside from current levels. In a report issued on June 12, Morgan Stanley also maintained a Buy rating on the stock with a $44.00 price target.

Jazz Pharmaceuticals (JAZZ)

In a report released today, Gregory Renza from Truist Financial maintained a Buy rating on Jazz Pharmaceuticals. The company’s shares closed last Wednesday at $226.93.

According to TipRanks.com, Renza is a 5-star analyst with an average return of 15.8% and a 47.2% success rate. Renza covers the Healthcare sector, focusing on stocks such as Ascentage Pharma Group International Unsponsored ADR, Perspective Therapeutics, and Abivax SA Sponsored ADR. ;'>

Jazz Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $262.93, implying a 14.6% upside from current levels. In a report issued on June 12, TD Cowen also maintained a Buy rating on the stock with a $275.00 price target.

Read More on SION:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).